michigan semaglutide gastrointestinal obstruction lawsuit Wegovy At least 3,000 patients have

Cagrisema (ecnoglutide) is a novel GLP1 agonist under study for weight loss

Ozempic contains no caffeine or stimulants

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity (LOE) wave that puts an estimated $200 billion to $400 billion in branded drug revenue at direct risk.

FullSpectrum

Akkermansia muciniphila Supports GLP-1 activity, strengthens the gut barrier, promotes metabolic balance

This systematic review evaluates the efficacy, tolerability, and neurobiological rationale of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonists in treating nicotine use disorder (NUD), with particular attention to smoking abstinence, craving reduction, weight gain mitigation, and mechanistic insights